Literature DB >> 11890317

Principal stratification in causal inference.

Constantine E Frangakis1, Donald B Rubin.   

Abstract

Many scientific problems require that treatment comparisons be adjusted for posttreatment variables, but the estimands underlying standard methods are not causal effects. To address this deficiency, we propose a general framework for comparing treatments adjusting for posttreatment variables that yields principal effects based on principal stratification. Principal stratification with respect to a posttreatment variable is a cross-classification of subjects defined by the joint potential values of that posttreatment variable tinder each of the treatments being compared. Principal effects are causal effects within a principal stratum. The key property of principal strata is that they are not affected by treatment assignment and therefore can be used just as any pretreatment covariate. such as age category. As a result, the central property of our principal effects is that they are always causal effects and do not suffer from the complications of standard posttreatment-adjusted estimands. We discuss briefly that such principal causal effects are the link between three recent applications with adjustment for posttreatment variables: (i) treatment noncompliance, (ii) missing outcomes (dropout) following treatment noncompliance. and (iii) censoring by death. We then attack the problem of surrogate or biomarker endpoints, where we show, using principal causal effects, that all current definitions of surrogacy, even when perfectly true, do not generally have the desired interpretation as causal effects of treatment on outcome. We go on to forrmulate estimands based on principal stratification and principal causal effects and show their superiority.

Mesh:

Substances:

Year:  2002        PMID: 11890317      PMCID: PMC4137767          DOI: 10.1111/j.0006-341x.2002.00021.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  17 in total

1.  Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring.

Authors:  C E Frangakis; D B Rubin
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

2.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

3.  On meta-analytic assessment of surrogate outcomes.

Authors:  M H Gail; R Pfeiffer; H C Van Houwelingen; R J Carroll
Journal:  Biostatistics       Date:  2000-09       Impact factor: 5.899

4.  Identifiability and exchangeability for direct and indirect effects.

Authors:  J M Robins; S Greenland
Journal:  Epidemiology       Date:  1992-03       Impact factor: 4.822

5.  More powerful randomization-based p-values in double-blind trials with non-compliance.

Authors:  D B Rubin
Journal:  Stat Med       Date:  1998-02-15       Impact factor: 2.373

6.  Estimating the proportion of treatment effect explained by a surrogate marker.

Authors:  D Y Lin; T R Fleming; V De Gruttola
Journal:  Stat Med       Date:  1997-07-15       Impact factor: 2.373

7.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

8.  The paired availability design: a proposal for evaluating epidural analgesia during labor.

Authors:  S G Baker; K S Lindeman
Journal:  Stat Med       Date:  1994-11-15       Impact factor: 2.373

9.  Regression analysis of grouped survival data: informative censoring and double sampling.

Authors:  S G Baker; Y Wax; B H Patterson
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

10.  On estimating efficacy from clinical trials.

Authors:  A Sommer; S L Zeger
Journal:  Stat Med       Date:  1991-01       Impact factor: 2.373

View more
  286 in total

1.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

2.  Estimating Causal Effects in Trials Involving Multi-Treatment Arms Subject to Non-compliance: A Bayesian framework.

Authors:  Qi Long; Roderick J A Little; Xihong Lin
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2010-05       Impact factor: 1.864

3.  Comparing biomarkers as principal surrogate endpoints.

Authors:  Ying Huang; Peter B Gilbert
Journal:  Biometrics       Date:  2011-04-22       Impact factor: 2.571

4.  Application of potential outcomes to an intentional weight loss latent variable problem.

Authors:  Gary L Gadbury; Thidaporn Supapakorn; Christopher S Coffey; Scott W Keith; David B Allison
Journal:  Stat Interface       Date:  2008       Impact factor: 0.582

5.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

6.  Principal stratification and attribution prohibition: good ideas taken too far.

Authors:  Marshall Joffe
Journal:  Int J Biostat       Date:  2011-09-14       Impact factor: 0.968

7.  Bounded, efficient and multiply robust estimation of average treatment effects using instrumental variables.

Authors:  Linbo Wang; Eric Tchetgen Tchetgen
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2017-12-18       Impact factor: 4.488

8.  Estimating Moderated Causal Effects with Time-varying Treatments and Time-varying Moderators: Structural Nested Mean Models and Regression with Residuals.

Authors:  Geoffrey T Wodtke; Daniel Almirall
Journal:  Sociol Methodol       Date:  2017-04-27

9.  Causal inference in randomized experiments with mediational processes.

Authors:  Booil Jo
Journal:  Psychol Methods       Date:  2008-12

10.  Assessing mediation using marginal structural models in the presence of confounding and moderation.

Authors:  Donna L Coffman; Wei Zhong
Journal:  Psychol Methods       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.